Skip Navigation


NDT Advance Access originally published online on September 27, 2006
Nephrology Dialysis Transplantation 2007 22(2):577-583; doi:10.1093/ndt/gfl560
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/2/577    most recent
gfl560v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Serra, A. L.
Right arrow Articles by Wüthrich, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serra, A. L.
Right arrow Articles by Wüthrich, R. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients

Andreas L. Serra1, Reto Savoca2, Andreas R. Huber2, Urs Hepp3, Aba Delsignore3, Martin Hersberger4 and Rudolf P. Wüthrich1

1Clinic for Nephrology, University Hospital, CH-8091 Zürich, 2Center for Laboratory Medicine, Kantonsspital, CH-5001 Aarau, 3Department of Psychiatry, University Hospital and 4Institute for Clinical Chemistry, University Hospital, CH-8091 Zürich, Switzerland

Correspondence and offprint requests to: Andreas L. Serra, MD, Clinic for Nephrology, University Hospital, Rämistrasse 100, 8091 Zürich, Switzerland. Email: andreas.serra{at}usz.ch



  Abstract

Background. Cinacalcet rapidly normalizes serum calcium and reduces intact parathyroid hormone (PTH) levels in renal transplant patients with hypercalcaemia and persistent hyperparathyroidism. The aim of this study is to evaluate the 6 months efficacy of cinacalcet and the effect of cinacalcet withdrawal on serum calcium and PTH in such patients. Furthermore, the impact of cinacalcet on bone turnover and quality of life was assessed.

Methods. Twelve renal allograft recipients with hypercalcaemia due to persistent hyperparathyroidism were treated with cinacalcet for 26 weeks. Cinacalcet was then withdrawn to check for recurrence of hypercalcaemia.

Results. Cinacalcet maintained normocalcaemia in all patients from week 4 to 26, and PTH significantly decreased and remained suppressed. Serum phosphate

increased, whereas the serum calcium–phosphate product remained unchanged. The excretion of calcium and phosphate in the 24 h urine had tendency to decrease. After cinacalcet was withdrawn, hypercalcaemia recurred rapidly and PTH increased to baseline values. Renal function remained stable, proteinuria was unchanged and no allograft rejection was observed. During treatment with cinacalcet, total and bone-specific alkaline phosphatase increased, whereas the urinary deoxypyridinoline–creatinine ratio did not change significantly, suggesting enhanced bone formation. Quality of life assessed at weeks 10 and 26 remained unchanged compared with baseline.

Conclusions. In conclusion, continued treatment with cinacalcet is required to maintain long-term normocalcaemia and to suppress the enhanced PTH production in renal transplant recipients with persistent hyperparathyroidism.

Keywords: calcium; cinacalcet; hypercalcaemia; hyperparathyroidism; kidney transplantation; PTH


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NDT PlusHome page
S. Goto, H. Komaba, and M. Fukagawa
Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
NDT Plus, August 1, 2008; 1(suppl_3): iii2 - iii8.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
M. Tanaka, S. Nakanishi, H. Komaba, K. Itoh, K. Matsushita, and M. Fukagawa
Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
NDT Plus, August 1, 2008; 1(suppl_3): iii49 - iii53.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Kamar, I. Gennero, L. Spataru, L. Esposito, J. Guitard, L. Lavayssiere, O. Cointault, P. Gandia, D. Durand, and L. Rostaing
Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose
Nephrol. Dial. Transplant., June 16, 2008; (2008) gfn345v1.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
U. Kunzendorf, B. K. Kramer, W. Arns, J. Braun, J. Grossmann, F. Pietruck, H. Schmidt-Gayk, A. Schwarz, E. Ziegler, H. Sperschneider, et al.
Bone disease after renal transplantation
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 450 - 458.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. E. Kruse, U. Eisenberger, F. J. Frey, and M. G. Mohaupt
Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2362 - 2365.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.